Inquiry Basket
Loading ......
Filter By Product Search for
CTSK
CTSK Full Name
cathepsin K
CTSK Introduction
Cathepsin K (CatK) is a lysosomal cysteine protease encoded by the CTSK gene and is widely recognized as one of the most efficient mammalian collagen-degrading enzymes. Although it is predominantly expressed by activated osteoclasts, Cathepsin K is also produced by macrophages, fibroblasts, synovial cells, vascular smooth muscle cells, and several epithelial cell types under physiological or inflammatory conditions. Its unique ability to cleave type I and type II collagen, elastin, and other extracellular matrix (ECM) proteins makes it indispensable for normal bone remodeling and tissue turnover. Because excessive or insufficient Cathepsin K activity directly alters extracellular matrix integrity, researchers increasingly monitor its expression as a biomarker of pathological tissue remodeling rather than simply a marker of osteoclast activity. Understanding Cathepsin K biology has therefore become essential for investigators studying bone metabolism, inflammatory disorders, fibrosis, cardiovascular disease, and cancer, where matrix degradation is a defining feature of disease progression and therapeutic response.
The primary biological function of Cathepsin K is to mediate osteoclast-driven bone resorption during skeletal remodeling. Following activation through the RANKL-RANK signaling pathway, mature osteoclasts acidify the bone resorption lacuna, creating an optimal environment for Cathepsin K to degrade collagen-rich bone matrix after mineral dissolution. Unlike many other lysosomal proteases, Cathepsin K exhibits exceptional collagenolytic and elastinolytic activity, allowing efficient breakdown of highly cross-linked extracellular proteins while maintaining the balance between bone resorption and bone formation. Beyond the skeleton, accumulating evidence demonstrates that Cathepsin K participates in extracellular matrix remodeling within the cardiovascular system, lungs, central nervous system, skin, adipose tissue, and immune microenvironment. It influences inflammatory signaling, macrophage activation, angiogenesis, tissue fibrosis, and vascular remodeling, highlighting its broader physiological importance. Because Cathepsin K integrates proteolysis with inflammatory and metabolic signaling networks, it has emerged as a valuable molecular target for mechanistic studies, drug discovery, and biomarker development across multiple therapeutic fields.
Abnormal regulation of Cathepsin K has been implicated in a broad spectrum of human diseases characterized by excessive extracellular matrix degradation or abnormal osteoclast activity. Elevated Cathepsin K expression is strongly associated with osteoporosis, osteoarthritis, rheumatoid arthritis, periodontitis, and osteolytic bone metastases, where enhanced osteoclast-mediated collagen degradation accelerates bone destruction. Increased Cathepsin K activity has also been reported in atherosclerosis, abdominal aortic aneurysm, pulmonary fibrosis, emphysema, tuberculosis, chronic inflammatory lung diseases, neurodegenerative disorders, obesity-related metabolic dysfunction, and multiple solid tumors, where it contributes to tissue invasion, inflammatory remodeling, angiogenesis, and metastatic progression. Conversely, inherited CTSK deficiency causes pycnodysostosis, a rare skeletal disorder characterized by impaired bone resorption despite increased bone density, illustrating the enzyme's indispensable physiological role. These diverse clinical associations have made Cathepsin K one of the most extensively investigated therapeutic targets in bone biology. Although early synthetic Cathepsin K inhibitors such as odanacatib demonstrated potent anti-resorptive efficacy, concerns regarding off-target cardiovascular and cerebrovascular adverse effects have shifted current research toward developing highly selective small molecules, antibody-based strategies, activity-responsive imaging probes, and naturally derived inhibitors with improved safety profiles. As understanding of Cathepsin K continues to expand beyond bone biology into systemic inflammatory and degenerative diseases, this protease remains an important biomarker and therapeutic target for translational research, precision medicine, and next-generation anti-remodeling therapies.
Alternate Names for CTSK
CTSK; cathepsin K; CTSO; PKND; PYCD; CTS02; CTSO1; CTSO2; cathepsin O; cathepsin X; cathepsin O1; cathepsin O2;
Loading ......
